Skip to main navigation Skip to search Skip to main content

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC

  • Fabrice Barlesi
  • , Edward B. Garon
  • , Dong Wan Kim
  • , Enriqueta Felip
  • , Ji Youn Han
  • , Joo Hang Kim
  • , Myung Ju Ahn
  • , Mary Jo Fidler
  • , Matthew A. Gubens
  • , Gilberto de Castro
  • , Veerle Surmont
  • , Qiao Li
  • , Anne C. Deitz
  • , Gregory M. Lubiniecki
  • , Roy S. Herbst
  • Aix-Marseille Université
  • University of California at Los Angeles
  • Seoul National University
  • Vall d'Hebron Institute of Oncology
  • National Cancer Center Korea
  • CHA University
  • Rush University Medical Center
  • University of California at San Francisco
  • Instituto do Cancer do Estado de São Paulo
  • Ghent University
  • Merck
  • Yale University

Research output: Contribution to journal › Article › peer-review

61   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience